{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:07:22Z","timestamp":1751623642601,"version":"3.40.4"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6216,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1996,3]]},"abstract":"<jats:p>The pharmacodynamic equipotency of 2 dose regimens (5 mg twice daily versus 10 mg once daily) of befloxatone, a new reversible and selective monoamine oxidase A (MAO\u2010A) inhibitor, after single and multiple doses for 6 days was examined in a randomized, double\u2010blind, three\u2010way crossover, placebo\u2010controlled trial of 12 healthy volunteers. Plasma levels of the deaminated metabolite 3\u20134 dihydroxyphenylglycol (DHPG), as measured by high\u2010performance liquid chromatography (HPLC) with coulometric electrochemical detection, were used as an index of MAO inhibition. A single dose of befloxatone produced a significant dose\u2010related reduction in plasma DHPG levels, as shown by the decrease in the 24\u2010hour area under the concentration\u2010time curve (AUC<jats:sub>0\u201324<\/jats:sub>) of DHPG, which peaked 2 hours after administration and persisted over 24 hours. Both dose regimens provided equipotent extent and duration of MAO\u2010A inhibition at steady state, suggesting a once daily dosage should be sufficient for most patients. The pharmacokinetic bioavailability at steady state of both dose regimens was also similar. The concentration\u2010time effect curve after a single dose revealed a hysteresis corresponding to the delay necessary to elicit MAO inhibition and\/or elimination of DHPG. The relationship between plasma levels of DHPG and\/or elimination of plasma concentrations of DHPG and befloxatone after a single dose can be modeled using the E<jats:sub>max<\/jats:sub>model with a mean EC<jats:sub>50<\/jats:sub>of 4.75 ng\/mL, and suggests the presence of a maximal response from the single dose. This model permits prediction of steady\u2010state levels of DHPG.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1996.tb04191.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:31:55Z","timestamp":1362767515000},"page":"216-229","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers"],"prefix":"10.1002","volume":"36","author":[{"given":"Alain","family":"Patat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"le Coz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dubruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Marc","family":"Gandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Cimarosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Jezequel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Curet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Zieleniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Allain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.146.6.576"},{"key":"e_1_2_1_3_2","first-page":"545","volume-title":"Psychopharmacology: The Third Generation of Progress.","author":"Murphy DL","year":"1987"},{"key":"e_1_2_1_4_2","first-page":"147","volume-title":"Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies.","author":"Martin L","year":"1994"},{"key":"e_1_2_1_5_2","first-page":"181","volume-title":"Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies.","author":"Quitkin FM","year":"1994"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.113.497.349"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60597-9"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243040-00009"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014438"},{"key":"e_1_2_1_10_2","first-page":"339","article-title":"Biochemical pharmacology of befloxatone (MD 370503), a new potent reversible MAO\u2010A inhibitor","volume":"41","author":"Rovei V","year":"1994","journal-title":"J Neural Transm"},{"key":"e_1_2_1_11_2","first-page":"3055","article-title":"Biochemical pharmacology of befloxatone, a reversible selective and competitive inhibitor of MAO\u2010A (abstract)","volume":"10","author":"Rovei V","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_1_12_2","first-page":"83","volume-title":"Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies.","author":"Bieck PR","year":"1994"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb05022.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00625795"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245010"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06919-4","article-title":"Multiple forms of monoamine oxidase: functional significance","volume":"24","author":"Sandler M","year":"1972","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90550-1"},{"key":"e_1_2_1_18_2","first-page":"282","article-title":"Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment","volume":"23","author":"Robinson DS","year":"1983","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(83)90058-7"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(85)90593-4"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90232-9"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113298"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1981.tb01678.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90336-8"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174063"},{"key":"e_1_2_1_26_2","first-page":"599P","article-title":"Plasma dihydroxyphenylglycol concentration: a simple, sensitive and specific index of monoamine oxidase\u2010A activity in vivo (abstract)","volume":"15","author":"Brown MJ","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05357.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90581-U"},{"key":"e_1_2_1_29_2","first-page":"349","article-title":"Effects of befloxatone, a new potent reversible MAO\u2010A inhibitor, on cortex and striatum monoamines in freely moving rats","volume":"41","author":"Curet O","year":"1994","journal-title":"J Neural Transm"},{"key":"e_1_2_1_30_2","first-page":"328B","article-title":"Phase I study of single ascending doses of befloxatone, a new reversible MAO\u2010A inhibitor antidepressant (abstract)","volume":"15","author":"Ansseau M","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470100206"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/32.11.2030"},{"key":"e_1_2_1_33_2","first-page":"559","volume-title":"Monoamine Oxidase and Disease.","author":"Brown MJ","year":"1984"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246235"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246239"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb05445.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543787"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198801000-00003"},{"key":"e_1_2_1_39_2","first-page":"57","article-title":"Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor","volume":"26","author":"Korn A","year":"1988","journal-title":"J Neural Transm"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1991.tb01904.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05710.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.155"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198606000-00001"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1996.tb04191.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1996.tb04191.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:38:59Z","timestamp":1745969939000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1996.tb04191.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["10.1002\/j.1552-4604.1996.tb04191.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04191.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}